BMRN
NASDAQ · Biotechnology
Biomarin Pharmaceutical Inc
$63.94
-1.14 (-1.75%)
Financial Highlights (FY 2026)
Revenue
3.22B
Net Income
348.24M
Gross Margin
81.4%
Profit Margin
10.8%
Rev Growth
+15.4%
D/E Ratio
0.10
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 81.4% | 81.4% | 64.4% | 64.4% |
| Operating Margin | 12.7% | 11.4% | -0.2% | -0.2% |
| Profit Margin | 10.8% | 10.3% | -0.2% | -0.2% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.22B | 2.79B | 1.41B | 1.49B |
| Gross Profit | 2.62B | 2.27B | 907.72M | 958.72M |
| Operating Income | 408.66M | 318.71M | -2,319,034 | -2,707,489 |
| Net Income | 348.24M | 271.59M | -2,303,166 | -2,253,505 |
| Gross Margin | 81.4% | 81.4% | 64.4% | 64.4% |
| Operating Margin | 12.7% | 11.4% | -0.2% | -0.2% |
| Profit Margin | 10.8% | 10.3% | -0.2% | -0.2% |
| Rev Growth | +15.4% | +15.4% | -7.9% | +19.9% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 563.24M | 563.24M | 2.64B | 3.18B |
| Total Equity | 5.74B | 5.74B | 3.48B | 3.90B |
| D/E Ratio | 0.10 | 0.10 | 0.76 | 0.82 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 428.06M | 352.39M | -4,073,088 | -4,182,603 |
| Free Cash Flow | — | — | -1,983,877 | -2,166,443 |